首页> 美国卫生研究院文献>Filaria Journal >Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis
【2h】

Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis

机译:L5加L3利什曼原虫主要核糖体蛋白组合疫苗与Th1佐剂联合对小鼠皮肤和内脏利什曼病的交叉保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTwo Leishmania major ribosomal proteins L3 (LmL3) and L5 (LmL5) have been described as protective molecules against cutaneous leishmaniasis due to infection with L. major and Leishmania braziliensis in BALB/c mice when immunized with a Th1 adjuvant (non-methylated CpG-oligodeoxynucleotides; CpG-ODN). In the present study we analyzed the cross-protective efficacy of an LmL3-LmL5-CpG ODN combined vaccine against infection with Leishmania amazonensis and Leishmania chagasi (syn. Leishmania infantum) the etiologic agents of different clinical forms of human leishmaniasis in South America.
机译:背景两种利什曼原虫主要核糖体蛋白L3(LmL3)和L5(LmL5)被描述为针对皮肤利什曼病的保护分子,因为在用Th1佐剂(非甲基化CpG-寡脱氧核苷酸; CpG-ODN)。在本研究中,我们分析了LmL3-LmL5-CpG ODN联合疫苗对南美利什曼原虫和婴儿利什曼原虫(婴儿利什曼原虫)的感染的交叉保护作用。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号